Lilly’s Retevmo Cuts Recurrence Risk 83%; $4.31B in New Collaborations
LLY•Eli Lilly’s Phase 3 data showed Retevmo reduced recurrence or death risk by 83% in early-stage RET fusion-positive non-small cell lung cancer. The company secured a $1.26 billion licensing deal with Hanmi and a $3.05 billion research alliance with Haisco, while shares fell 2.7% premarket.
1. Phase 3 Retevmo Trial Results
Eli Lilly’s Retevmo demonstrated a statistically significant 83% reduction in risk of disease recurrence or death compared with control in patients with early-stage RET fusion-positive non-small cell lung cancer. The trial evaluated Retevmo as an adjuvant therapy following surgical resection, marking a critical step toward broadening its use beyond advanced RET-driven cancers.
2. Hanmi and Haisco Collaboration Deals
The company entered a licensing agreement with Hanmi Pharmaceutical for sonefpeglutide, a short bowel syndrome candidate, structured for up to $1.26 billion in milestones and royalties. In parallel, Lilly launched a multi-program research alliance with Haisco Pharmaceutical potentially worth up to $3.05 billion, aiming to co-develop novel biotherapeutics across multiple disease targets.
3. Market Reaction and Next Catalysts
Despite the trial success and strategic partnerships, shares declined 2.7% in premarket trading, suggesting investors may be awaiting detailed safety data and regulatory timelines. Key upcoming catalysts include submission of new drug applications for adjuvant Retevmo use and updates on sonefpeglutide’s clinical progress and market launch plans.
